Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease

American Journal of Hematology

Volumn 85, Issue 10, 2010, Pages 795-797

  Stallworth, James R ^a   Jerrell, Jeanette M ^a   Tripathi, Avnish ^b  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYUREA;

ACUTE CHEST SYNDROME; ADOLESCENT; ARTICLE; CHILD HOSPITALIZATION; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CRITICALLY ILL PATIENT; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAID; OUTPATIENT CARE; PAIN; PNEUMONIA; PRIORITY JOURNAL; SICKLE CELL ANEMIA; VEIN OCCLUSION; ANEMIA, SICKLE CELL; CHILD; COMPLICATION; COST; COST BENEFIT ANALYSIS; ECONOMICS; EMERGENCY HEALTH SERVICE; EVALUATION STUDY; HOSPITAL COST; HOSPITALIZATION; OUTPATIENT DEPARTMENT; POVERTY; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ACUTE CHEST SYNDROME; ADOLESCENT; ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; HYDROXYUREA; MALE; MEDICAID; OUTPATIENT CLINICS, HOSPITAL; PAIN; POVERTY; SOUTH CAROLINA; UNITED STATES;

EID: 77957666296     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21772     Document Type: Article

References (30)

1. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference Statement: Hydroxyurea treatment for sickle cell disease. Ann Intern Med 2008;148:932-938.
2. Raphael JL, Dietrich CL, Whitmire D, et al. Healthcare utilization and expenditures for low income children with sickle cell disease. Pediatr Blood Cancer 2009;52:263-267.
3. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-1644.
4. Leikin SL, Gallagher D, Kinney TR, et al. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics 1989;84:500-508.
5. Powars DR, Schroeder WA, Weiss JN, et al. Lack of influence of fetal hemoglobin levels or erythrocyte indices on the severity of sickle cell anemia. J Clin Invest 1980;65:732-740.
6. Powars DR, Weiss JN, Chan LS, et al. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood 1984;63:921-926.
7. DeBaun MR, Vichinsky E.Hemoglobinopathies. In: Kliegman RM,Behrman RE,Jenson HB,Stanton B, editors. Nelson Textbook of Pediatrics.18th ed. Philadelphia, Pa: WB Saunders Elsevier; 2007. Available at http://www.mdconsult. com/das/book/body/143898456-9/853444084/1608/1067.html#4-u1.0-B978-1-4160-2450- 7.50464-3-cesec19-8724. Accessed June 17, 2009.
8. Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: Effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992;79:2555-2565.
9. Odenheimer DJ, Sarnaik SA, Whitten CF, et al. The relationship between fetal hemoglobin and disease severity in children with sick cell anemia. Am J Med Genet 1987;27:525-535.
10. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease: Rates and risk factors. N Engl J Med 1991;325:11-16.
11. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999;94:1550-1554.
12. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial. Blood 1996;88:1960-1964.
13. Jayabose S, Tugal O, Sandoval C, et al. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr 1996;129:559-565.
14. Strouse JJ, Lanzkron S, Beach MC, Haywood C, Jr., Park H, Witkop C, Wilson RF, Bass EB, Segal JB. Hydroxyurea for sickle cell disease: A systematic review for efficacy and toxicity in children. Pediatrics 2008;122:1332-1342.
15. Scott JP, Hillery CA, Brown ER, et al. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr 1996;128:820-828.
16. Brandow AM, Brousseau DC, Panepinto JA. Postdischarge pain, functional limitations and impact on caregivers of children with sickle cell disease treated for painful events. Br J Haematol 2009;144:782-788.
17. Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease. Am J Hematol 2009;84:323-327.
18. Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Am J Hematol 2000;64:26-31.
19. Lanzkron S, Haywood C Jr., Segal JB, Dover GJ. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematol 2006;81:927-932.
20. Ijaduola GT, Akinyanju OO. Chronic tonsillitis, tonsillectomy and sickle cell crises. J Laryngol Otol 1987;101:467-470.
21. Maddern BR, Reed HT, Ohene-Frempong K, Beckerman RC. Obstructive sleep apnea syndrome in sickle cell disease. Ann Otol Rhinol Laryngol 1989;98:174-178.
22. Mvundura M, Amendah D, Kavanagh PL, Sprinz PG, Grosse SD. Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States. Pediatr Blood Cancer 2009;53:642-646.
23. Stevens GD, Shi L. Racial and ethnic disparities in the primary care experiences of children: A review of the literature. Med Care Res Rev 2003;60:3-30.
24. Haywood C Jr., Beach MC, Lanzkron S, Strouse JJ, Wilson R, Park H, Witkop C, Bass EB, Segal JB. A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease. J Natl Med Assoc 2009;101:1022-33.
25. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea. Blood 1997;89:1078-1088.
26. Handel DA, McConnell KJ, Wallace N, Gallia C. How much does emergency department use affect the cost of Medicaid programs? Ann Emerg Med 2008;51:614-621.
27. Unutzer J, Simon G, Pabiniak C, Bond K, Katon W. The use of administrative data to assess quality of care for bipolar disorders in a large staff model HMO. Gen Hosp Psychiatry 2000;22:1-10.
28. Mark TL, Buck JA, Dilonardo JD, Coffey RM, Chalk M. Medicaid expenditures on behavioral health care. Psychiatr Serv 2003;54:188-194.
29. Hennessy S, Leonard CE, Freeman CP, Deo R, Newcomb C, Kimmel SE, Strom BL, Bilker WB. Validation of diagnostic codes for outpatient-originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data. Pharmacoepidemiol Drug Saf 2009 Oct 20 [epub ahead of print].
30. Chibnik LB, Massarotti EM, Costenbader KH. Identification and validation of lupus nephritis cases using administrative data. Lupus 2010;19(6):741-743.